Advertisement

Advertisement

1Eilish Scallan, MD, FRCPC,2Daniel Warshafsky, MD, FRCPC,3Jane Purvis, MD, FRCP(C),

1Dr. Eilish Scallan is a public health and primary care physician. She currently holds the role of Associate Regional Medical Officer of Health with the Nova Scotia Health Authority, and is an Assistant Clinical Professor in the Department of Family Medicine at McMaster University in Hamilton, Ontario. Affiliations: Assistant Clinical Professor, Department of Family Medicine, McMaster University, Hamilton, ON. 2Dr. Daniel Warshafsky is a Public Health and Sports Medicine Physician. He currently holds the role of Associate Chief Medical Officer of Health for the Office of the Chief Medical Officer of Health in Ontario and is an Adjunct Lecturer at the University of Toronto’s Dalla Lana School of Public Health, and an Assistant Professor at Queen’s University’s Department of Family and Community Medicine. Affiliations: Ontario Ministry of Health, Toronto, ON. 3 is a rheumatologist, the chair of the Ontario Medical Association Medical Network and a member of the OMA Health Policy Panel.

CLINICAL TOOLS

Abstract: Patients with autoimmune inflammatory rheumatic diseases face elevated infection risk from immune dysregulation and immunosuppressive therapy. This article summarizes National Advisory Committee on Immunization recommendations, supplemented by Canadian Rheumatology Association and American College of Rheumatology guidance. It reviews general principles, including live vaccine deferral and medication timing, and vaccine-specific advice for influenza, COVID-19, zoster, pneumococcus, HPV, RSV, measles, and tetanus. Proactive vaccine review and medication coordination reduce preventable infectious morbidity.
Key Words: vaccination, rheumatic diseases, immunosuppression, NACI, live-attenuated vaccines.
1. Non-live vaccines are recommended for most immunocompromised patients, though immunosuppression may reduce their efficacy. Live-attenuated vaccines should generally be deferred in patients on significant immunosuppression.
2. Most immunosuppressive medications can be continued around non-live vaccination, with notable exceptions: methotrexate (influenza) and B-cell depleting therapies.
3. Core vaccines for this population include annual influenza, twice-yearly COVID-19 (mRNA preferred), recombinant zoster, pneumococcal conjugate (Pneu-C-20 or -21), HPV, and RSV, with age- and risk-based criteria for each.
4. Publicly funded schedules vary by province and territory, so clinicians should check local guidelines before administering vaccines.
Time vaccines around therapy. Methotrexate can be held for 2 weeks after influenza vaccination if disease activity permits, as it significantly blunts immunogenicity. For B-cell depleting agents such as rituximab, vaccinate when the next dose is due, then hold the drug for at least 2 weeks afterward.
Vaccinate against zoster early. Complete the recombinant zoster series (2 doses, 2–6 months apart) at least 14 days before starting immunosuppression when possible. If time is short, the second dose can be given as early as 4 weeks after the first.
Don’t let prior infection or uncertain history delay vaccination. COVID-19 vaccination should proceed regardless of prior infection, and one Pneu-C-20 or -21 dose is recommended regardless of prior pneumococcal vaccine history. If measles immunity status is unknown, vaccination is preferred over serology, though live vaccines remain subject to deferral in those on immunosuppression.
To have access to full article that these tools were developed for, please subscribe. The cost to subscribe is $80 USD per year and you will gain full access to all the premium content on www.healthplexus.net, an educational portal, that hosts 1000s of clinical reviews, case studies, educational visual aids and more as well as within the mobile app.
Disclaimer: 
Disclaimer at the end of each page